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Abstract. In recent years, studies have suggested that 
promoter methylation in human papilloma virus (HPV) posi-
tive head and neck squamous cell carcinoma (HNSCC) has 
a mechanistic role and has the potential to improve patient 
survival. The present study aimed to replicate key molecular 
findings from previous analyses of the methylomes of HPV 
positive and HPV negative HNSCC in an independent cohort, 
to assess the reliability of differentially methylated markers in 
HPV-associated tumors. HPV was measured using real-time 
quantitative PCR and the biological significance of methyla-
tion differences was assessed by Ingenuity Pathway Analysis 
(IPA). Using an identical experimental design of a 450K 
methylation platform, 7 of the 11 genes were detected to be 
significantly differentially methylated and all 11 genes were 
either hypo- or hypermethylated, which was in agreement 
with the results of a previous study. IPA's enriched networks 
analysis identified one network with msh homeobox 2 (MSX2) 
as a central node. Locally dense interactions between genes in 
networks tend to reflect significant biology; therefore MSX2 
was selected as an important gene. Sequestration in the top 
four canonical pathways was noted for 5‑hydroxytryptamine 
receptor 1E (serotonin signaling), collapsin response mediator 
protein 1 (semaphorin signaling) and paired like homeodo-
main 2 (bone morphogenic protein and transforming growth 
factor‑β signaling). Placement of 9 of the 11 genes in highly 
ranked pathways and bionetworks identified key biological 
processes to further emphasize differences between HNSCC 
HPV positive and negative pathogenesis.
Introduction
The results from a number of studies involving next‑generation 
sequencing sequence analysis, gene expression microarrays, 
whole‑exome sequencing and genome‑wide methylation 
studies support the observation that human papilloma virus 
(HPV) positive squamous head and neck cancer (HNSCC) 
is a distinct entity and therefore exhibits a particular set of 
somatic alterations (1-6). Data from epidemiological and 
clinical studies have also indicated that HPV positive HNSCC 
is clinically different from HPV negative HNSCC in terms of 
patient characteristics, sensitivity to treatment and molecular 
biology (7,8).
Global characterization of the HNSCC methylome 
demonstrates the different landscapes in HPV positive tumors 
compared with HPV negative tumors. CpG methylation is 
higher in HPV positive cells in both repetitive and non-repet-
itive regions (genic and non-genic) (9,10). Methylome analysis 
of HPV positive and HPV negative primary formalin‑fixed 
paraffin‑embedded tumors using the Illumina HumanMeth-
ylation450K Beadchip platform (2) have confirmed previous 
reports (9,11) that the DNA methylation signature of HPV 
positive HNSCC is different from that of HPV negative 
HNSCC and that HPV positive HNSCC has a strong tendency 
to undergo hypermethylation. A previous study (2) highlighted 
11 genes: Chromosome 14 open reading frame 162/coiled-coil 
domain containing 177 (C14orf162/CCDC177), cadherin 8 
(CDH8), collapsin response mediator protein 1 (CRMP1), 
engulfment and cell motility 1 (ELMO1), 5‑hydroxytrypta-
mine receptor 1E (HTR1E), meiotic double-stranded break 
formation protein 1 (MEI1), msh homeobox 2 (MSX2), 
protocadherin 10 (PCDH10), protocadherin β-11 (PCDHB11), 
paired like homeodomain 2 (PITX2) and synapsin II (SYN2) 
as undergoing significantly different methylation processes in 
HPV positive and HPV negative HNSCC (2) (Table I).
It has been established that patients with HPV posi-
tive HNSCC have better survival outcomes than those with 
HNSCC that are HPV negative, possibly due to improved 
responses to chemoradiation (12). However, it remains unclear 
why HPV positive patients experience improved prognoses‑the 
underlying mechanisms responsible for these outcomes have 
not yet been investigated. A mechanistic role for promoter 
methylation is beginning to be established, with the aim of 
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improving survival outcomes of patients with HPV positive 
HNSCC (13). The aim of the current study was to verify that 
the 11 aforementioned genes undergo significantly different 
methylation in HPV positive and HPV negative HNSCC 
tumor samples and to assess their biological significance using 
Ingenuity Pathway Analysis (IPA) for biomarker potential in 
HPV-associated HNSCC.
Materials and methods
DNA extraction and amplification. DNA from 4 HPV posi-
tive and 4 HPV negative freshly frozen (‑80˚C) primary 
HNSCC tumor samples, resected from patients admitted 
between December 2010 and January 2012 in the Depart-
ment of Otolaryngology/Head and Neck Surgery (Henry Ford 
Hospital, Detroit, USA), were subjected to comprehensive 
genome‑wide methylation profiling using the Infinium Human-
Methylation450K BeadChip kit (Illumina, Inc., San Diego, 
CA, USA). Tumor site and demographic characteristics are 
presented in Table II. For the present study, patient informed 
consent for inclusion of surgically resected tissues was given, 
and the study was approved by the Henry Ford Health System 
Institutional Review Board committee.
DNA was extracted according to the manufacturer's 
protocol (Qiagen, Inc., Valencia, CA, USA). Tumor HPV 
DNA concentrations were measured using real‑time quanti-
tative PCR (qPCR) as previously described (14,15). Briefly, 
primers and probes to a housekeeping gene (β-globin) were 
run in parallel to standardize the input DNA. By using serial 
dilutions, standard curves were developed for the HPV viral 
copy number using CaSki (American Type Culture Collection, 
Manassas, VA, USA) cell line genomic DNA, which have 
600 copies/genome equivalent (6.6 pg of DNA/genome). The 
cut‑off value for HPV16 positive status was >0.03 (>3 HPV 
genome copy/100 cells) (14-16).
The Infinium HumanMethylation450 BeadChip kit 
includes 485,764 cytosine positions in the human genome 
and covers 99% of Reference Sequence genes. The Reference 
Sequence collection aims to provide an integrated, comprehen-
sive, well‑annotated non‑redundant set of sequences, including 
genomic DNA, transcripts and proteins (17). The interrogated 
CpG sites are distributed among all 23 human chromosome 
pairs (17).
Processing samples for the Infinium HumanMethylation450. 
The Infinium HumanMethylation450 assays were performed 
at the Applied Genomics Technology Center, Wayne State 
University (Detroit, MI, USA). Following DNA checks of 
original DNA quality, quantification and bisulfite conversion, 
4 µl of bisulfite‑converted DNA was used for hybridization 
according to Illumina Infinium methylation protocols. Data 
were normalized using the Controls Normalization method 
(Illumina, Inc.). The methylation score for each CpG was 
represented as a beta (β) value according to the fluorescence 
intensity ratio and each β‑value in the Infinium HumanMethyl-
ated450 BeadChip kit was accompanied by a detection P‑value. 
β-values could take any value between 0 (non-methylated) 
and 1 (completely methylated) and were determined using 
the GenomeStudio® 2009.2, Methylation Module ver. 1.5.5., 
ver. 3.2 (Illumina, Inc.). Probes were discarded if P>0.05. All 
normalized and raw data were submitted to the GEO (Gene 
Expression Omnibus, NCBI) according to the instructions 
provided (GEO accession numbers: GSE67114). The resulting 
β‑values were exported to Microsoft Excel, JMP and SAS 
(SAS Institute, Inc., Cary, NC, USA) for data analysis.
Pathway analysis. To determine the biological processes 
occurring within the 11 differentially methylated genes, 
they were uploaded to the Ingenuity pathway Analysis (IPA; 
Ingenuity Systems, Inc; Qiagen, Inc.). IPA integrates genes 
and molecules that are part of the same biological functions 
or regulatory networks interacting together.
Statistical methods. There was a priori evidence that the 
11 genes were differentially methylated and each in a partic-
ular direction, therefore, P<0.05 was considered to indicate a 
statistically significant difference.
Results
HumanMethylation450K BeadChip analysis. For all genes, 
99.97% of the CpGs and 100% of the CpGs associated with 
the 11 genes of particular interest, met the detection threshold 
of P<0.05 and therefore were eligible for analysis.
Of the 11 genes of interest, the methylation status of 7 
differed significantly between HPV positive and HPV nega-
tive HNSCC (Table I). CDH8, PCDHB11, ELMO1, MSX2, 
and HTR1E were significantly hypermethylated and MEI1 
and C14orf162/CCDC177 were significantly hypomethyl-
ated (Fig. 1). The methylation status of all 11 genes as either 
hypo‑ or hypermethylated was consistent with the results of a 
previous study by Lechner et al (2) even though the methyla-
tion of four genes did not differ significantly (P>0.05).
Pathway analysis. C14orf162/CCDC177 was excluded from 
the list of genes in IPA as it was unaccounted for in the IPA 
knowledge database. IPA connected 7/10 genes in a 35 gene 
network characterized by the following functions: Cellular 
Development, Skeletal and Muscular System Development 
and Function, and Embryonic Development as the sole 
enriched top network (Fig. 2). The seven genes exhibiting 
significantly different methylation were MSX2, CRMP1, 
ELMO1, CDH8, SYN2, PCDH10 and PITX2 (Fig. 1).
The top five molecular and cellular functions included 
cell morphology, cellular assembly, cellular movement, 
cell-to-cell signaling and interaction and cell death and 
survival (Table III). ELMO1 was represented in all the top 
five functions followed by MSX2 and PTX2 (4/5); CRMP1 
and SYN2 (3/5); PCDHB11 (2/5); and CDH8, HTR1E and 
PCDH10 (1/5).
The highly ranked canonical pathways (P<0.05) indicate 
sequestration of HTR1E in serotonin receptor signaling, 
CRMP1 in sematophorin signaling, and PITX2 in bone 
morphogenic protein (BMP) and transforming growth factor 
(TGF) β signaling (Table IV).
Discussion
Squamous cell carcinomas primarily develop in the larynx, 
pharynx and oral cavity, and make up the vast majority of 
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mucosal head and neck cancer (18). It has been challenging to 
accurately and reliably stratify HNSCC to predict outcomes, 
primarily due to the numerous anatomic sites and subsites 
from which tumors can arise. Globally, 600,000 people are 
annually diagnosed with HNSCC (19). The number of cases of 
HNSCC has gradually increased over the past three decades and 
currently account for 5% of all malignancies (20).
Just two risk factors, tobacco and alcohol (21) are respon-
sible for 72% of HNSCC cases (22). However, previous studies 
have also implicated HPV status as a possible cause of certain 
Table I. Infinium HumanMethylation450 Beadchip assay data for HPV positive vs. HPV negative HNSCC samples for 11 genes. 
     Ratio of 
  HPV   HPV positive
Gene name Chromosome status Mean β SD vs. HPV negative P‑value Methylation
C14orf162/CCDC177 14 Positive 0.161 0.041 0.579 0.019a Hypo
  Negative 0.278 0.034
CDH8   4 Positive 0.479 0.062 1.640 0.004a Hyper
  Negative 0.292 0.055
CRMP1   4 Positive 0.208 0.058 1.155 0.749 Hyper
  Negative 0.180 0.058
ELMO1   7 Positive 0.578 0.067 1.234 0.026a Hyper
  Negative 0.468 0.033
HTR1E   6 Positive 0.433 0.062 1.357 0.027a Hyper
  Negative 0.319 0.060
MEI1 22 Positive 0.318 0.072 0.849 0.008a Hypo
  Negative 0.531 0.087
MSX2   5 Positive 0.394 0.081 2.213 0.009a Hyper
  Negative 0.178 0.065
PCDH10   4 Positive 0.333 0.103 1.524 0.166 Hyper
  Negative 0.220 0.023
PCDHB11   5 Positive 0.548 0.074 1.302 0.042a Hyper
  Negative 0.421 0.076
PITX2   4 Positive 0.416 0.112 1.386 0.138 Hyper
  Negative 0.300 0.088
SYN2   3 Positive 0.399 0.115 1.013 0.781 Hyper
  Negative 0.394 0.104
aP<0.05, indicates a statistically significant difference. Cohort of 8 samples (4 HPV+HNSCC, 4 HPV‑HNSCC). HNSCC, head and neck 
squamous cell carcinoma; HPV, human papilloma virus; chrom, chromosome; SD, standard deviation; meth, methylation status; hypo, hypo-
methylated; hyper, hypermethylated; C14orf162/CCDC177; chromosome 14 open reading frame 162/coiled‑coil domain containing 177; 
CDH8, cadherin 8; CRMP1, collapsin response mediator protein 1; ELMO1, engulfment and cell motility 1; HTR1E, 5‑hydroxytryptamine 
receptor 1E; MEI1, meiotic double‑stranded break formation protein 1; MSX2, msh homeobox 2; PCDH10, protocadherin 10; PCDHB11, 
protocadherin β‑11; PITX2, paired like homeodomain 2; SYN2, synapsin II.
Table II. Patient cohort.
Tissue ID Site Age Ethnicity Gender HPV status
HFHS‑HN19 Oropharynx 60 AA M Positive
HFHS‑HN28 Oropharynx 64 CA M Positive
HFHS‑HN30 Oropharynx 62 AA M Positive
HFHS‑HN48 Tonsil 53 CA M Positive
HFHS‑HN51 Larynx 49 CA M Negative
HFHS‑HN23 Larynx 67 AA M Negative
HFHS‑HN26 Tongue 71 CA M Negative
HFHS‑HN42 Oropharynx 66 AA F Negative
AA, African American; CA, caucasian; M, male; F, female; HPV, human papilloma virus. 
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HNSCC cases (23) and an independent risk factor for oropha-
ryngeal cancer (OPSCC) (24). The biological significance of 
HPV as an additional independent risk factor is highlighted 
by the improved prognosis of patients with HPV positive 
Figure 2. Top network. IPA identified ‘Cellular Development, Skeletal and Muscular System Development and Function, Embryonic Developmentʼ as the only 
enriched top network. This network is built with 35 genes from IPA's knowledgebase and includes 7 (MSX2, CRIMP1, ELMO1, CDH8, SYN2, PDCH10, PITX2) 
of the 11 differentially methylated genes (highlighted in red). MSX2, msh homeobox 2; CRIMP1, collapsing response mediator protein 1; ELMO1, engulfement 
and cell motility 1; CDH8, cadherin 8; SYN2, synapsin II; PDCH10, protocadherin 10; PITX2, paired like homeodomain 2.
Figure 1. Illumina 450K methylation beadchip beta values associated with HPV positive and HPV negative HNSCC. Of 11 differentially methylated genes, 
7 demonstrate statistically significant differential methylation in HPV positive vs. HPV negative HNSCC (*P<0.05). For all 11 genes, hypermethylation and 
hypomethylation directional changes were concordant with the results from Lechner et al (2). Among these genes, MEI1 and C14orf162 were hypomethylated 
and the remaining 9 were hypermethylated. Differences in methylation in HPV negative and HPV positive HNSCC were significant in 7 of the genes analyzed. 
HPV, human papilloma virus; HNSCC, head and neck squamous cell carcinoma; C14orf162/CCDC177; chromosome 14 open reading frame 162/coiled-coil 
domain containing 177; CDH8, cadherin 8; CRMP1, collapsin response mediator protein 1; ELMO1, engulfment and cell motility 1; HTR1E, 5‑hydroxytrypta-
mine receptor 1E; MEI1, meiotic double‑stranded break formation protein 1; MSX2, msh homeobox 2; PCDH10, protocadherin 10; PCDHB11, protocadherin 
β‑11; PITX2, paired like homeodomain 2; SYN2, synapsin II.
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HNSCC compared to HPV negative HNSCC (23,24), which 
may partly be due to improved therapeutic responses to 
chemoradiotherapy (12).
It has been demonstrated that HPV positive OPSCC is a 
distinct type of HNSCC characterized by overexpression of 
cyclin‑dependent kinase inhibitor 2A (CDKN2A), improved 
patient prognoses, nonkeratinizing histology and a high preva-
lence of HPV infection (25). At present, HPV status is the most 
robust and valid molecular diagnostic and prognostic biomarker 
for HNSCC (26). The expression of E6 and E7 HPV oncoproteins 
may influence the genetic profile of HPV positive HNSCC (23). 
HPV positive tumors are characterized by E6 suppression of 
wild‑type p53 function (27), retinoblastoma pathway inactiva-
tion by E7 and overexpression of wild‑type CDKN2A (28), 
and infrequent amplification of cyclin D (29), whereas for 
HPV-HNSCC, the opposite occurs (30). Tumor protein 53 muta-
tions are detected in all HPV negative cases and in the majority 
of HPV negative tumors, downregulation of CDKN2A and/or 
cyclin D1 amplification occur (1). The improved prognosis of 
HPV positive patients compared to HPV negative HNSSC 
patients has been confirmed (12,16,24), however the mechanistic 
explanation for this phenomenon remains elusive.
Continuing to adapt the idea of assessing the methylation 
status of patients with HPV positive HNSCC compared to 
those with HPV negative HNSCC, Lechner et al (2), analyzed 
32 cases of HNSCC (18 HPV positive and 14 HPV negative), 
detected 11 genes that were methylated differently between 
HPV positive and HPV negative HNSCC and analyzed mRNA 
expression for two genes: CDH8 and PCDH10. The mRNA 
expression data for the remaining 9 genes were obtained from 
a different study by Pyeon et al (6). The study also confirmed 
previous reports (9,11) that HPV positive patients have a 
distinct DNA methylation signature from their HPV negative 
HNSCC counterparts.
The present study, in an independent HNSCC sample set 
using an identical experimental design of the 450K methyla-
tion platform, confirmed that 7 of the 11 aforementioned genes 
were significantly differentially methylated. Additionally, 
replication of complete concordance of methylation direction 
(hypo‑ vs. hypermethylated) was observed for all 11 genes. A 
recent analysis demonstrated that 9 genes, CDH8, CRMP1, 
ELMO1, HTR1E, MEI1, MSX2, PCDHB11, PITX2, SYN2, 
were observed to be significantly differentially methylated in 
HPV positive compared to HPV negative HNSCC (31).
Differentially methylated genes can be investigated by the 
pathway analysis framework, which is able to identify distinct 
signaling pathway networks and therefore may provide a 
biological basis for further exploration of methylated genes as 
differential targets in HPV positive and HPV negative HNSCC. 
In this type of analysis, a biological system is surveyed in the 
context of a specific phenotype for example, the context of 
disease, to identify gene groups associated with biological 
systems (32,33). The pairing of biological relationships allows 
for a strategic knowledge base approach and has been used 
to improve understanding of the systems biology of disease 
processes and more intuitively identify potential therapeutic 
targets (34-36).
A previous study by our group (5) demonstrated that 
genes involved in signal transduction pathways of HPV 
positive HNSCC tumor genomes exhibited a predominant 
hypermethylation profile. In the current study, 9 of the 11 
genes that were represented in IPA's top functions, path-
ways and networks were hypermethylated. Hypomethylated 
C14orf162 was not registered in IPA's knowledge database 
and thus was not included in pathway analyses. Hypometh-
ylated MEI1 did not place among significantly ranked 
pathways/functions/networks. C14orf162/CCDC177, also 
Table III. Top molecular and cellular functions. 
Name P‑value Differentially methylated genes
Cell‑to‑cell signalling and interaction <0.0001‑0.028a PCDHB11, HTR1E, CDH8, PITX2, ELMO1, MSX2, SYN2
Cellular movement <0.0001‑0.048a CRMP1, PCDH10, PITX2, ELMO1, MSX2
Cellular assembly and organization <0.001‑0.027a PCDHB11, CRMP1, ELMO1, SYN2
Cell death and survival  <0.001‑0.038a PITX2, ELMO1, MSX2
Cell morphology <0.001‑0.04a CRMP1, PITX2, SYN2, ELMO1, MSX2
aP<0.05; indicates a statistically significant result. C14orf162/CCDC177; chromosome 14 open reading frame 162/coiled-coil domain containing 
177; CDH8, cadherin 8; CRMP1, collapsin response mediator protein 1; ELMO1, engulfment and cell motility 1; HTR1E, 5‑hydroxytryptamine 
receptor 1E; MEI1, meiotic double‑stranded break formation protein 1; MSX2, msh homeobox 2; PCDH10, protocadherin 10; PCDHB11, 
protocadherin β‑11; PITX2, paired like homeodomain 2; SYN2, synapsin II.
Table IV. Top canonical pathways. 
  (Name) of
  differentially 
  methylated 
  genes/total 
Pathway P-value pathway genes
Serotonin receptor signaling 0.02a 1 (HTR1E)/33
Semaphorin signaling in neurons 0.03a 1 (CRMP1)/52
BMP signaling  0.04a 1 (PITX2)/80
TGF-β signaling 0.056 1 (PITX2)/89
aP<0.05; HTR1E, 5‑hydroxytryptamine receptor 1E; CRMP1, 
collapsin response mediator protein 1; PITX2, paired like home-
odomain 2; BMP, bone morphogenic protein; TGF‑β, transforming 
growth factor β.
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known as myelin proteolipid protein-like protein, is encoded 
by a gene that maps to human chromosome 14q24.1. MEI1 is 
expressed almost exclusively in the gonads and is required for 
normal vertebrate meiotic chromosome synapsis (37). Its role 
in cancer has not yet been investigated and the results of the 
present study suggest opportunities for additional studies to 
further investigate the mechanism by which MEI1 operates in 
cancer.
The IPA network generation algorithm iteratively 
constructs networks that strive for optimization of the number 
of focus genes (10 in the current study) and interconnectivity, 
under the constraint of a maximum network size of 35 genes. 
The former identifies how user‑specified genes interact with 
each other or with neighboring genes, thus highlighting the 
molecular biology implied in a dataset. In the present study, 
IPA's enriched networks analysis produced only one network: 
Cellular development, skeletal and muscular system develop-
ment and function and embryonic development. This network 
included 7/10 focus genes, MSX2, CRMP1, ELMO1, CDH8, 
SYN2, PCDH10, PITX2 that completed the 35 gene network 
from IPA's knowledgebase. Locally dense interactions 
between genes tend to reflect significant biology therefore, the 
role of the MSX2 gene in particular has been highlighted as 
significant.
MSX2 is a homeobox gene implicated in bone metabolism, 
organ development, and breast and colorectal tumorigen-
esis (38-41). Its involvement in HPV-associated HNSCC has 
been previously documented (2) and was confirmed in the 
present independent study, which presents additional rationale 
for further investigations into the role of MSX2 in HNSCC.
ELMO1 was represented in all top five functions, followed 
by MSX2 and PTX2 (4/5), CRMP1 and SYN2 (3/5), PCDHB11 
(2/5), and CDH8, HTR1E, and PCDH10 (1/5) (Table III). 
ELMO1 is an evolutionarily conserved cytoplasmic engulf-
ment protein that promotes actin-dependent phagocytosis 
and cell migration in a number of invertebrate models and 
immortalized mammalian cell lines (42). Its role in tumori-
genesis and increased invasiveness has been investigated in 
glioma cells (43), esophageal adenocarcinoma (44) and breast 
cancer (45). Furthermore, it has been demonstrated that hyper-
methylated ELMO1 was part of one of the three methylation 
epigenotypes for colorectal cancer (46).
The top four canonical pathways indicated the inclusion of 
HTR1E, CRMP1 and PITX2. HTR1E is one of the 33 genes 
in the highest ranked serotonin receptor signaling canonical 
pathway (Table IV). Serotonin (5‑HT) is a growth factor and 
a cell cycle mediator that regulates DNA synthesis (47). In 
the mammalian nervous system, 5‑HT receptors are part of 
the superfamily of G‑protein‑coupled receptors. Treatment of 
tumor cells with EGF (Epidermal Growth Factor) and 5-HT 
may decrease the number of G0/G1 cells that are dormant, 
resulting in more active, dividing cells that consequently 
have increased sensitivity to chemotherapeutic treatment (48). 
Differential methylation of the promoters of HTR1E has been 
detected in patients with schizophrenia (49).
CRMPs are cytosolic phosphoproteins involved in axonal 
guidance and neuronal differentiation (50). CRMP1 is one 
of 52 genes in the second ranked semaphorin signaling 
canonical pathway implicated in semaphorin-induced 
growth cone collapse during neural development and axonal 
guidance (50). Semaphorin signaling affects focal adhesion 
assembly/disassembly and induces cytoskeletal remodeling, 
which consequently impacts cell motility, cell shape, cell 
migration and attachment to the extracellular matrix (51). 
Oncology studies are thus increasingly focused on axon guid-
ance molecules.
CRMP1 has been characterized as a novel invasion‑suppres-
sion gene. It has been demonstrated that low expression of 
CRMP1 mRNA in lung cancer tissue is significantly associ-
ated with lymph node metastasis, early post-operative relapse, 
advanced disease and shorter patient survival times (52). How 
CRMP1 inhibits cell invasion remains unclear, however, DNA 
methylation in the context of a hypermethylated CRMP1 
suggests low expression and therefore implicates epigenetic 
mechanisms in HNSCC tumorigenesis.
The PITX2 gene was placed in 4/5 of the top molecular 
and cellular functions (Table III) and two of the four top 
canonical pathways (Table IV). PITX2 is 1 of 80 genes in 
the BMP and 1 of 89 genes in the TGF‑β signaling pathways. 
TGF-β/BMP signaling pathways are involved in bone forma-
tion during mammalian development with various regulatory 
functions (53) and their disruptions have been implicated in 
multiple bone diseases, including tumor metastasis (54). PITX2 
encodes a transcription factor of the paired‑like homeodomain 
protein family, a crucial component during normal embryonic 
development (55) that has diverse roles in cell differentiation, 
proliferation, organogenesis and hematopoiesis (56,57). PITX2 
is downstream of TGF‑β and fibroblast growth factor (FGF) 
signaling and may regulate cell proliferation by activating the 
expression of cyclins D1 and D3 (58). It has been demonstrated 
that methylation of PITX2 in human tumorigenesis occurs in 
several types of human cancer, including colon, breast, ovarian 
and prostate cancer (59-61). A previous study indicated that 
PITX2 downregulation with associated promoter hypermeth-
ylation predicted good clinical outcomes following radical 
prostatectomy (61).
Confirmation of hypermethylation of CDH8 and PCDHB11 
in the independent sample set of the current study is consis-
tent with findings from previous studies demonstrating that 
cadherin genes are targets for transcriptional silencing in 
HNSCC and HPV-mediated hypermethylation (2). Cadherins 
are targets of Polycomb repressive complex 2 and are involved 
in different types of cancer and cancer specific processes (62) 
including the epithelial to mesenchymal transition, a process 
that facilitates cell invasion and metastasis (63). Polycomb 
group target genes are more likely to contain cancer‑specific 
promoter DNA hypermethylation than other genes (64). This 
supports the theory that cancer originates from the stem cells, 
where permanent silencing replaces reversible gene expression 
thus locking the cell into a perpetual state of self‑renewal that 
predisposes it to malignant transformation (65).
In conclusion, the current study investigated an independent 
HNSCC sample set. The concordance of methylation direction 
(hypo‑ vs. hypermethylated) from previous analyses of the 
methylomes of HPV positive and HPV negative HNSCC was 
replicated for all 11 genes. Of the 11 genes, 9 were represented 
in IPA's top functions, pathways and network, and 7 genes were 
reported as undergoing significantly different methylation. The 
present study suggests that cadherins CDH8 and PCDHB11, 
together with C14orf162/CCDC177, ELMO1, HTR1E MEI1 
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and MSX2, are biomarkers for HPV‑associated HNSCC. Cell 
signaling events are critical in the execution of key biological 
functions and insights into how complex cellular signaling 
cascades and networks are programmed may be important in 
aiding the development of novel biological agents with multiple 
targets. Placement of 9 of the 11 genes in key pathways and 
biological processes focuses attention on the unique biological 
processes in HPV‑associated HNSCC tumors and identify the 
differences between the pathogenesis of HPV positive and 
HPV negative HNSCC at the epigenetic level.
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